Opko Health Inc. (NASDAQ:OPK) Short Interest Update

Opko Health Inc. (NASDAQ:OPK) was the recipient of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 74,550,000 shares, a decline of 12.1% from the September 30th total of 84,770,000 shares. Based on an average trading volume of 4,830,000 shares, the short-interest ratio is presently 15.4 days. Approximately 19.5% of the shares of the company are sold short.

A number of research analysts have commented on the stock. Barrington Research restated a “buy” rating and issued a $4.00 price objective on shares of Opko Health in a research note on Thursday, September 12th. BidaskClub lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, October 29th. ValuEngine upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research upgraded shares of Opko Health from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research note on Friday, October 18th.

Shares of NASDAQ OPK traded up $0.06 on Friday, hitting $1.49. The company’s stock had a trading volume of 10,885,900 shares, compared to its average volume of 8,227,058. Opko Health has a 12-month low of $1.33 and a 12-month high of $3.93. The stock has a 50 day moving average of $1.81 and a 200-day moving average of $1.99. The company has a market capitalization of $951.81 million, a price-to-earnings ratio of -5.96 and a beta of 2.17. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.08 and a quick ratio of 0.90.

Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Opko Health had a negative return on equity of 14.42% and a negative net margin of 30.98%. The business had revenue of $228.80 million during the quarter, compared to analyst estimates of $225.40 million. During the same period in the previous year, the company earned ($0.05) EPS. Opko Health’s revenue was down 8.4% on a year-over-year basis. Sell-side analysts expect that Opko Health will post -0.43 EPS for the current fiscal year.

In other Opko Health news, Director Richard C. Pfenniger, Jr. acquired 25,000 shares of the company’s stock in a transaction on Friday, October 25th. The shares were bought at an average cost of $1.45 per share, for a total transaction of $36,250.00. Following the completion of the purchase, the director now owns 275,000 shares in the company, valued at approximately $398,750. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Vice Chairman Jane Ph D. Hsiao acquired 400,000 shares of the company’s stock in a transaction on Friday, October 25th. The stock was acquired at an average price of $1.50 per share, for a total transaction of $600,000.00. Following the completion of the purchase, the insider now owns 24,475,147 shares of the company’s stock, valued at approximately $36,712,720.50. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 3,290,000 shares of company stock valued at $4,907,750. 42.25% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OPK. BlackRock Inc. boosted its stake in Opko Health by 4.4% during the 2nd quarter. BlackRock Inc. now owns 31,520,785 shares of the biotechnology company’s stock valued at $76,910,000 after acquiring an additional 1,330,639 shares during the last quarter. Vanguard Group Inc. boosted its stake in Opko Health by 2.7% during the 2nd quarter. Vanguard Group Inc. now owns 30,467,543 shares of the biotechnology company’s stock valued at $74,341,000 after acquiring an additional 812,237 shares during the last quarter. Northern Trust Corp boosted its stake in Opko Health by 4.4% during the 2nd quarter. Northern Trust Corp now owns 4,195,696 shares of the biotechnology company’s stock valued at $10,238,000 after acquiring an additional 175,185 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Opko Health by 5.7% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 2,387,816 shares of the biotechnology company’s stock valued at $5,827,000 after acquiring an additional 128,250 shares during the last quarter. Finally, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management boosted its stake in Opko Health by 98.4% during the 2nd quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 2,092,606 shares of the biotechnology company’s stock valued at $5,106,000 after acquiring an additional 1,037,669 shares during the last quarter. 24.58% of the stock is owned by institutional investors and hedge funds.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

See Also: Monthly Dividend Stocks Can Provide Solid Income

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.